OPKO Health, Inc. (NASDAQ:OPK) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lessened its holdings in OPKO Health, Inc. (NASDAQ:OPK) by 42.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 856,738 shares of the biotechnology company’s stock after selling 634,254 shares during the quarter. Assenagon Asset Management S.A.’s holdings in OPKO Health were worth $1,265,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Rubric Capital Management LP boosted its stake in OPKO Health by 9.6% in the 3rd quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock worth $72,573,000 after purchasing an additional 4,284,336 shares in the last quarter. PFG Investments LLC raised its holdings in shares of OPKO Health by 10.4% in the third quarter. PFG Investments LLC now owns 1,061,090 shares of the biotechnology company’s stock worth $1,581,000 after buying an additional 100,125 shares during the last quarter. Clearline Capital LP purchased a new stake in shares of OPKO Health during the third quarter valued at $1,083,000. Barclays PLC increased its position in shares of OPKO Health by 154.5% in the 3rd quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock valued at $810,000 after acquiring an additional 329,870 shares during the period. Finally, Squarepoint Ops LLC acquired a new position in shares of OPKO Health in the 2nd quarter valued at $592,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of OPKO Health in a research note on Wednesday, January 8th. StockNews.com lowered OPKO Health from a “hold” rating to a “sell” rating in a research report on Wednesday, January 15th. Finally, Barrington Research reiterated an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a report on Friday, November 8th.

Insider Transactions at OPKO Health

In other news, CEO Phillip Md Et Al Frost bought 100,000 shares of the stock in a transaction dated Thursday, November 14th. The shares were acquired at an average cost of $1.62 per share, with a total value of $162,000.00. Following the purchase, the chief executive officer now directly owns 211,612,405 shares in the company, valued at $342,812,096.10. The trade was a 0.05 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have bought 1,954,255 shares of company stock valued at $2,985,105 in the last 90 days. 47.26% of the stock is currently owned by company insiders.

OPKO Health Stock Performance

NASDAQ OPK opened at $1.49 on Friday. The firm has a market capitalization of $1.02 billion, a P/E ratio of -7.84 and a beta of 1.63. The stock has a 50-day simple moving average of $1.54 and a two-hundred day simple moving average of $1.51. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. OPKO Health, Inc. has a fifty-two week low of $0.86 and a fifty-two week high of $1.76.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.13. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The company had revenue of $173.60 million during the quarter, compared to analysts’ expectations of $181.32 million. During the same period last year, the business earned ($0.11) earnings per share. On average, equities analysts forecast that OPKO Health, Inc. will post -0.25 earnings per share for the current year.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.